A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer) [0.03%]
CheckMate 9DW研究的通俗概述：纳武利尤单抗联合伊匹木单抗治疗不可切除性肝细胞癌（晚期肝癌）
Thomas Yau,Peter R Galle,Thomas Decaens et al.
Thomas Yau et al.
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01 [0.03%]
沙楚帕利布联合雄激素受体途径抑制剂在转移性雄激素敏感性前列腺癌中的应用：EvoPAR-Prostate01研究
Arun A Azad,Neeraj Agarwal,Andrew J Armstrong et al.
Arun A Azad et al.
Poly(ADP-ribose) polymerase (PARP) inhibitor plus androgen receptor pathway inhibitor (ARPI) is approved for selected patients with metastatic castration-resistant prostate cancer. Saruparib (AZD5305) is a new-generation PARP inhibitor that...
Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study [0.03%]
中国复发和难治性多发性骨髓瘤的治疗模式：一项针对医生的真实世界调查研究
Di Wu,Bhavna Murali,Otavio Clark et al.
Di Wu et al.
Background: Multiple Myeloma (MM) is a complex hematologic malignancy with a rapidly evolving therapeutic landscape. Real-world data on treatment regimen use beyond the first line in China are limited. ...
Early hematologic dynamics and their association with patient-reported symptom burden in breast cancer pharmacotherapy: a prospective cohort study [0.03%]
乳腺癌药物治疗的早期血液动力学及其与患者报告的症状负担之间的关联：前瞻性队列研究
Henry Sutanto,Merlyna Savitri,Een Hendarsih et al.
Henry Sutanto et al.
Background: Systemic pharmacotherapy for breast cancer frequently induces hematologic toxicity and inflammatory changes that may affect symptom burden and treatment tolerance. This study evaluated baseline hematologic pro...
Lorlatinib in patients with ALK-positive metastatic NSCLC previously treated with an ALK inhibitor: results from a phase IV study [0.03%]
用于治疗既往接受过ALK抑制剂的ALK阳性转移性非小细胞肺癌患者的劳拉替尼：来自一项Ⅳ期研究的结果
Alessandra Bearz,Serena Ricciardi,Nirmal Vivek Raut et al.
Alessandra Bearz et al.
Aims: This post-approval study was conducted to confirm efficacy of lorlatinib in anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) that progressed on one prior second-generation ALK ...
Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer [0.03%]
DUO-E研究结果的通俗概述：德瓦鲁单抗联合或不联合奥拉帕利治疗晚期子宫内膜癌患者的疗效
Shannon N Westin,Kathleen Moore,Hye Sook Chon et al.
Shannon N Westin et al.
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC [0.03%]
一项关于索拉莫拉斯替和派姆单抗联合或不联合化疗治疗KRAS G12C突变型非小细胞肺癌的创新性SUNRAY-01研究方案
Solange Peters,Maximilian Hochmair,Kathryn C Arbour et al.
Solange Peters et al.
www.clinicaltrials.gov identifier is NCT06119581. EudraCT: 2023-503412-33-00. Keywords: KRAS; NSCLC; Study d...
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study [0.03%]
阿利珠单抗联合塞美利尤单抗治疗晚期免疫耐药性转移性非小细胞肺癌的多中心二期临床研究
Eziafa I Oduah,Tian Zhang,Sin-Ho Jung et al.
Eziafa I Oduah et al.
Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing ...
Real-world efficacy of first-line immunochemotherapy combined with thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer: a single-center retrospective study [0.03%]
一线免疫化疗联合胸部放疗治疗广泛期小细胞肺癌老年患者的疗效分析：单中心回顾性研究
Fengxin Sun,Shuangqing Lu,Meng Wu et al.
Fengxin Sun et al.
Background: Extensive-stage small cell lung cancer (ES-SCLC) carries a poor prognosis. Although first-line chemoimmunotherapy (IO+ChT) is standard, evidence in elderly patients (≥70 years) and the role of thoracic radiot...
Clinical risk factors and predictive value of inflammatory biomarkers for 2-year recurrence after standard surgery for endometrial cancer: a retrospective study among the Chinese population [0.03%]
子宫内膜癌标准手术治疗后两年复发的临床危险因素及炎症生物标志物的预测价值：一项基于中国人群的研究
Kalibinuer Kelaimu,Changji Xiao,Lirong Zhu et al.
Kalibinuer Kelaimu et al.
Aims: This study aimed to identify risk factors for recurrence after surgery for endometrial carcinoma in Chinese patients and to develop a postoperative surveillance model integrating preoperative biomarkers with postope...